Isoniazid pharmacokinetics-pharmaco dynamics in an aerosol infection model of tuberculosis

被引:139
作者
Jayaram, R [1 ]
Shandil, RK [1 ]
Gaonkar, S [1 ]
Kaur, P [1 ]
Suresh, BL [1 ]
Mahesh, BN [1 ]
Jayashree, R [1 ]
Nandi, V [1 ]
Bharath, S [1 ]
Kantharaj, E [1 ]
Balasubramanian, V [1 ]
机构
[1] AstraZeneca India Pvt Ltd, Bangalore 560024, Karnataka, India
关键词
D O I
10.1128/AAC.48.8.2951-2957.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Limited data exist on the pharmacokinetic-pharmacodynamic (PK-PD) parameters of the bactericidal activities of the available anti mycobacterial drugs. We report on the PK-PD relationships for isoniazid. Isoniazid exhibited concentration (C)-dependent killing of Mycobacterium tuberculosis H37Rv in vitro, with a maximum reduction of 4 log(10) CFU/ml. In these studies, 50% of the maximum effect was achieved at a C/MIC ratio of 0.5, and the maximum effect did not increase with exposure times of up to 21 days. Conversely, isoniazid produced less than a 0.5-log(10) CFU/mI reduction in two different intracellular infection models (J774A.1 murine macrophages and whole human blood). In a murine model of aerosol infection, isoniazid therapy for 6 days produced a reduction of 1.4 log(10) CFU/lung. Dose fractionation studies demonstrated that the 24-h area under the concentration-time curve/MIC (r(2) = 0.83) correlated best with the bactericidal efficacy, followed by the maximum concentration of drug in serum/MIC (r(2) = 0.73).
引用
收藏
页码:2951 / 2957
页数:7
相关论文
共 19 条
[11]  
MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6.771
[12]  
Mitchison DA, 2000, INT J TUBERC LUNG D, V4, P796
[13]   INTRACELLULAR GROWTH OF PATHOGENIC MYCOBACTERIA IN THE CONTINUOUS MURINE MACROPHAGE CELL-LINE J-774 - ULTRASTRUCTURE AND DRUG-SUSCEPTIBILITY STUDIES [J].
RASTOGI, N ;
POTAR, MC ;
DAVID, HL .
CURRENT MICROBIOLOGY, 1987, 16 (02) :79-92
[14]   High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids [J].
Seifart, HI ;
Gent, WL ;
Parkin, DP ;
vanJaarsveld, PP ;
Donald, PR .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 674 (02) :269-275
[15]   Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages [J].
Seral, C ;
Van Bambeke, F ;
Tulkens, PM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2283-2292
[16]   COMPARISON OF ACTIVITIES OF FLUOROQUINOLONES IN MURINE MACROPHAGES INFECTED WITH MYCOBACTERIUM-TUBERCULOSIS [J].
SKINNER, PS ;
FURNEY, SK ;
KLEINERT, DA ;
ORME, IM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (03) :750-753
[17]   A GUINEA-PIG MODEL OF EXPERIMENTAL AIRBORNE TUBERCULOSIS FOR EVALUATION OF THE RESPONSE TO CHEMOTHERAPY - THE EFFECT ON BACILLI IN THE INITIAL PHASE OF TREATMENT [J].
SMITH, DW ;
BALASUBRAMANIAN, V ;
WIEGESHAUS, E .
TUBERCLE, 1991, 72 (03) :223-231
[18]   Whole blood bactericidal activity during treatment of pulmonary tuberculosis [J].
Wallis, RS ;
Vinhas, SA ;
Johnson, JL ;
Ribeiro, FC ;
Palaci, M ;
Peres, RL ;
Sá, RT ;
Dietze, R ;
Chiunda, A ;
Eisenach, K ;
Ellner, JJ .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (02) :270-278
[19]   A whole blood bactericidal assay for tuberculosis [J].
Wallis, RS ;
Palaci, M ;
Vinhas, S ;
Hise, AG ;
Ribeiro, FC ;
Landen, K ;
Cheon, SH ;
Song, HY ;
Phillips, M ;
Dietze, R ;
Ellner, JJ .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (08) :1300-1303